Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic

Herein we evaluate the impact of COVID-19 restrictions on antidepressant effectiveness of intravenous (IV) ketamine in adults with treatment-resistant depression (TRD). We conducted a case series analysis of adults with TRD (n = 267) who received four ketamine infusions at an outpatient clinic in On...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenblat, Joshua D., Lipsitz, Orly, Di Vincenzo, Joshua D., Rodrigues, Nelson B., Kratiuk, Kevin, Subramaniapillai, Mehala, Lee, Yena, Arekapudi, Anil K., Abrishami, Amir, Chau, Edmond H., Szpejda, Witold, Wong, Leslie, Mansur, Rodrigo B., McIntyre, Roger S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240444/
https://www.ncbi.nlm.nih.gov/pubmed/34246008
http://dx.doi.org/10.1016/j.psychres.2021.114086
_version_ 1783715219263979520
author Rosenblat, Joshua D.
Lipsitz, Orly
Di Vincenzo, Joshua D.
Rodrigues, Nelson B.
Kratiuk, Kevin
Subramaniapillai, Mehala
Lee, Yena
Arekapudi, Anil K.
Abrishami, Amir
Chau, Edmond H.
Szpejda, Witold
Wong, Leslie
Mansur, Rodrigo B.
McIntyre, Roger S.
author_facet Rosenblat, Joshua D.
Lipsitz, Orly
Di Vincenzo, Joshua D.
Rodrigues, Nelson B.
Kratiuk, Kevin
Subramaniapillai, Mehala
Lee, Yena
Arekapudi, Anil K.
Abrishami, Amir
Chau, Edmond H.
Szpejda, Witold
Wong, Leslie
Mansur, Rodrigo B.
McIntyre, Roger S.
author_sort Rosenblat, Joshua D.
collection PubMed
description Herein we evaluate the impact of COVID-19 restrictions on antidepressant effectiveness of intravenous (IV) ketamine in adults with treatment-resistant depression (TRD). We conducted a case series analysis of adults with TRD (n = 267) who received four ketamine infusions at an outpatient clinic in Ontario, Canada, during COVID-19 restrictions (from March 2020 - February 2021; n = 107), compared to patients who received treatment in the previous year (March 2019 - February 2020; n = 160). Both groups experienced significant and comparable improvements in depressive symptoms, suicidal ideation, and anxiety with repeated ketamine infusions. Effectiveness of IV ketamine was not attenuated during the COVID-19 period.
format Online
Article
Text
id pubmed-8240444
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-82404442021-06-29 Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic Rosenblat, Joshua D. Lipsitz, Orly Di Vincenzo, Joshua D. Rodrigues, Nelson B. Kratiuk, Kevin Subramaniapillai, Mehala Lee, Yena Arekapudi, Anil K. Abrishami, Amir Chau, Edmond H. Szpejda, Witold Wong, Leslie Mansur, Rodrigo B. McIntyre, Roger S. Psychiatry Res Short Communication Herein we evaluate the impact of COVID-19 restrictions on antidepressant effectiveness of intravenous (IV) ketamine in adults with treatment-resistant depression (TRD). We conducted a case series analysis of adults with TRD (n = 267) who received four ketamine infusions at an outpatient clinic in Ontario, Canada, during COVID-19 restrictions (from March 2020 - February 2021; n = 107), compared to patients who received treatment in the previous year (March 2019 - February 2020; n = 160). Both groups experienced significant and comparable improvements in depressive symptoms, suicidal ideation, and anxiety with repeated ketamine infusions. Effectiveness of IV ketamine was not attenuated during the COVID-19 period. Elsevier B.V. 2021-09 2021-06-29 /pmc/articles/PMC8240444/ /pubmed/34246008 http://dx.doi.org/10.1016/j.psychres.2021.114086 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Short Communication
Rosenblat, Joshua D.
Lipsitz, Orly
Di Vincenzo, Joshua D.
Rodrigues, Nelson B.
Kratiuk, Kevin
Subramaniapillai, Mehala
Lee, Yena
Arekapudi, Anil K.
Abrishami, Amir
Chau, Edmond H.
Szpejda, Witold
Wong, Leslie
Mansur, Rodrigo B.
McIntyre, Roger S.
Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic
title Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic
title_full Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic
title_fullStr Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic
title_full_unstemmed Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic
title_short Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic
title_sort real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the covid-19 pandemic
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240444/
https://www.ncbi.nlm.nih.gov/pubmed/34246008
http://dx.doi.org/10.1016/j.psychres.2021.114086
work_keys_str_mv AT rosenblatjoshuad realworldeffectivenessofrepeatedketamineinfusionsfortreatmentresistantdepressionduringthecovid19pandemic
AT lipsitzorly realworldeffectivenessofrepeatedketamineinfusionsfortreatmentresistantdepressionduringthecovid19pandemic
AT divincenzojoshuad realworldeffectivenessofrepeatedketamineinfusionsfortreatmentresistantdepressionduringthecovid19pandemic
AT rodriguesnelsonb realworldeffectivenessofrepeatedketamineinfusionsfortreatmentresistantdepressionduringthecovid19pandemic
AT kratiukkevin realworldeffectivenessofrepeatedketamineinfusionsfortreatmentresistantdepressionduringthecovid19pandemic
AT subramaniapillaimehala realworldeffectivenessofrepeatedketamineinfusionsfortreatmentresistantdepressionduringthecovid19pandemic
AT leeyena realworldeffectivenessofrepeatedketamineinfusionsfortreatmentresistantdepressionduringthecovid19pandemic
AT arekapudianilk realworldeffectivenessofrepeatedketamineinfusionsfortreatmentresistantdepressionduringthecovid19pandemic
AT abrishamiamir realworldeffectivenessofrepeatedketamineinfusionsfortreatmentresistantdepressionduringthecovid19pandemic
AT chauedmondh realworldeffectivenessofrepeatedketamineinfusionsfortreatmentresistantdepressionduringthecovid19pandemic
AT szpejdawitold realworldeffectivenessofrepeatedketamineinfusionsfortreatmentresistantdepressionduringthecovid19pandemic
AT wongleslie realworldeffectivenessofrepeatedketamineinfusionsfortreatmentresistantdepressionduringthecovid19pandemic
AT mansurrodrigob realworldeffectivenessofrepeatedketamineinfusionsfortreatmentresistantdepressionduringthecovid19pandemic
AT mcintyrerogers realworldeffectivenessofrepeatedketamineinfusionsfortreatmentresistantdepressionduringthecovid19pandemic

Ejemplares similares